The purpose of this observational study is to describe the time to lipid-lowering drug implementation in the management of dyslipidemic patients, according to the cardiovascular risk level.
Study Type
OBSERVATIONAL
Enrollment
3,655
time to lipid-lowering drug implementation (immediately, treatment within a period 0-3 month and > 3 month, according to the cardiovascular risk level, (0 risk factor, 1 risk factor, 2 risk factors, ≥ 3 risk factors, secondary prevention).
Time frame: Once
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Research Site
Abbaretz, France
Research Site
Abbeville, France
Research Site
Ablon-sur-Seine, France
Research Site
Abrest, France
Research Site
Agde, France
Research Site
Agen, France
Research Site
Ahuy, France
Research Site
Aignay-le-Duc, France
Research Site
Aigre, France
Research Site
Aigues-Mortes, France
...and 1188 more locations